These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 33420414)
21. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27 Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665 [TBL] [Abstract][Full Text] [Related]
22. Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes. Xiao L; Gao R; Lu S; Ren L; Wang Z J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):735-7. PubMed ID: 17357504 [TBL] [Abstract][Full Text] [Related]
23. LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p. Sun H; Sun Y; Chen Q; Xu Z Life Sci; 2020 Jan; 241():117161. PubMed ID: 31837329 [TBL] [Abstract][Full Text] [Related]
24. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685 [TBL] [Abstract][Full Text] [Related]
25. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. Bourguignon LY; Spevak CC; Wong G; Xia W; Gilad E J Biol Chem; 2009 Sep; 284(39):26533-46. PubMed ID: 19633292 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway. Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474 [TBL] [Abstract][Full Text] [Related]
27. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Han J; Wang JZ; Yang X; Yu H; Zhou R; Lu HC; Yuan WB; Lu JC; Zhou ZJ; Lu Q; Wei JF; Yang H Mol Cancer; 2019 Jun; 18(1):110. PubMed ID: 31228940 [TBL] [Abstract][Full Text] [Related]
28. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer. Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542 [TBL] [Abstract][Full Text] [Related]
30. METTL3-mediated m6A modification promotes processing and maturation of Gong Y; Jiang Q; Liu L; Liao Q; Yu J; Xiang Z; Luo X Physiol Genomics; 2022 Sep; 54(9):337-349. PubMed ID: 35759451 [TBL] [Abstract][Full Text] [Related]
31. A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer. Huo Q; Yuan J; Zhu T; Li Z; Xie N Recent Pat Anticancer Drug Discov; 2021; 16(3):393-406. PubMed ID: 33602075 [TBL] [Abstract][Full Text] [Related]
32. Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis. Chang X; Liu Z; Cao S; Bian J; Zheng D; Wang N; Guan Q; Wu Y; Zhang W; Li Z; Zuo D Toxicol Appl Pharmacol; 2022 Feb; 436():115883. PubMed ID: 35031325 [TBL] [Abstract][Full Text] [Related]
34. Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. Li Y; Sun Y; Tang T; Niu Y; Li X; Xie M; Jin H; Mei Q J Ethnopharmacol; 2019 Mar; 232():47-54. PubMed ID: 30552993 [TBL] [Abstract][Full Text] [Related]
35. N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1. Bao J; Xu T; Wang W; Xu H; Chen X; Xia R Mol Cell Biochem; 2024 Nov; 479(11):3077-3089. PubMed ID: 38180718 [TBL] [Abstract][Full Text] [Related]
36. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Yi D; Xu L; Wang R; Lu X; Sang J Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043 [TBL] [Abstract][Full Text] [Related]
37. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant. Li T; Kong AN; Ma Z; Liu H; Liu P; Xiao Y; Jiang X; Wang L Oncotarget; 2016 Apr; 7(15):20236-48. PubMed ID: 26934120 [TBL] [Abstract][Full Text] [Related]
38. Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. Zhou S; Li J; Xu H; Zhang S; Chen X; Chen W; Yang S; Zhong S; Zhao J; Tang J Gene; 2017 Jul; 622():1-12. PubMed ID: 28431975 [TBL] [Abstract][Full Text] [Related]
39. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Zhong S; Li W; Chen Z; Xu J; Zhao J Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196 [TBL] [Abstract][Full Text] [Related]
40. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer. Li S; Jiang F; Chen F; Deng Y; Pan X J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]